Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy.

about

Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy.

Item

http://www.wikidata.org/entity/Q55163909

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Synthetic vaccine particles fo ...... and anti-tumor immunotherapy.

@en

Synthetic vaccine particles fo ...... and anti-tumor immunotherapy.

@nl

type

Item

label

Synthetic vaccine particles fo ...... and anti-tumor immunotherapy.

@en

Synthetic vaccine particles fo ...... and anti-tumor immunotherapy.

@nl

prefLabel

Synthetic vaccine particles fo ...... and anti-tumor immunotherapy.

@en

Synthetic vaccine particles fo ...... and anti-tumor immunotherapy.

@nl

P1476

Synthetic vaccine particles fo ...... s and anti-tumor immunotherapy

@en

P2093

Alicia M Michaud

http://www.w3.org/2001/XMLSchema#string

Conlin P O'Neil

http://www.w3.org/2001/XMLSchema#string

Dmitry A Ovchinnikov

http://www.w3.org/2001/XMLSchema#string

Fen-Ni Fu

http://www.w3.org/2001/XMLSchema#string

Grigoriy I Kovalev

http://www.w3.org/2001/XMLSchema#string

Lloyd P M Johnston

http://www.w3.org/2001/XMLSchema#string

Mikhail A Pechenkin

http://www.w3.org/2001/XMLSchema#string

Natalia M Drefs

http://www.w3.org/2001/XMLSchema#string

Takashi Kei Kishimoto

http://www.w3.org/2001/XMLSchema#string

P2860

Therapeutic cancer vaccines: past, present, and future

Perspectives for therapeutic HPV vaccine development

Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

Chimeric antigen receptor T cells for sustained remissions in leukemia

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia.

Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells.

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.

P304

e0197694

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0197694

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Chad J Roy

Petr O Ilyinskii

P577

2018-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29856772

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

lymphocyte

P932

5983463

http://www.w3.org/2001/XMLSchema#string